Quarterly paliperidone injection for patients with schizophrenia

Trevicta (paliperidone palmitate) is a 3-monthly sustained-release injection for the maintenance treatment of schizophrenia. It can be given once patients are clinically stable on monthly paliperidone palmitate injection (Xeplion).

The extended dosing interval of Trevicta may help to reduce the risk of relapse caused by poor adherence to treatment.

Further information
View Trevicta drug record
Summary of Product Characteristics
Manufacturer: Janssen-Cilag

Trevicta is administered by intramuscular injection into the deltoid or gluteal muscle, with dose adjustments when required within the range of 175mg to 525mg.

Similar to other antipsychotics, the most common adverse effects experienced by patients given the quarterly paliperidone palmitate injection included insomnia, extrapyramidal effects, weight change, hyperglycaemia, urinary tract infection, upper respiratory tract infection and headache.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.